Title
Effect of Shared Decision-Making for Stroke Prevention on Treatment Adherence and Safety Outcomes in Patients With Atrial Fibrillation: A Randomized Clinical Trial
Date Issued
18 January 2022
Access level
open access
Resource Type
journal article
Author(s)
Noseworthy P.A.
Branda M.E.
Kunneman M.
Hargraves I.G.
Sivly A.L.
Brito J.P.
Burnett B.
Linzer M.
Suzuki T.
Lee A.T.
Gorr H.
Jackson E.A.
Hess E.
Brand-Mccarthy S.R.
Shah N.D.
Clinica Mayo, Rochester
Clinica Mayo, Rochester
Publisher(s)
American Heart Association Inc.
Abstract
BACKGROUND: Guidelines promote shared decision-making (SDM) for anticoagulation in patients with atrial fibrillation. We recently showed that adding a within-encounter SDM tool to usual care (UC) increases patient involvement in decision-making and clinician satisfaction, without affecting encounter length. We aimed to estimate the extent to which use of an SDM tool changed adherence to the decided care plan and clinical safety end points. METHODS AND RESULTS: We conducted a multicenter, encounter-level, randomized trial assessing the efficacy of UC with versus without an SDM conversation tool for use during the clinical encounter (Anticoagulation Choice) in patients with nonvalvular atrial fibrillation considering starting or reviewing anticoagulation treatment. We conducted a chart and pharmacy review, blinded to randomization status, at 10 months after enrollment to assess primary adherence (proportion of patients who were prescribed an anticoagulant who filled their first prescription) and secondary adherence (estimated using the proportion of days for which treatment was supplied and filled for direct oral anticoagulant, and as time in therapeutic range for warfarin). We also noted any strokes, transient ischemic attacks, major bleeding, or deaths as safety end points. We enrolled 922 evaluable patient encounters (Anticoagulation Choice=463, and UC=459), of which 814 (88%) had pharmacy and clinical follow-up. We found no differences between arms in either primary adherence (78% of patients in the SDM arm filled their first prescription versus 81% in UC arm) or secondary adherence to anticoagulation (percentage days covered of the direct oral anticoagulant was 74.1% in SDM versus 71.6% in UC; time in therapeutic range for warfarin was 66.6% in SDM versus 64.4% in UC). Safety outcomes, mostly bleeds, occurred in 13% of participants in the SDM arm and 14% in the UC arm. CONCLUSIONS: In this large, randomized trial comparing UC with a tool to promote SDM against UC alone, we found no significant differences between arms in primary or secondary adherence to anticoagulation or in clinical safety outcomes. REGISTRATION: URL: https://www.clini​caltr​ials.gov; Unique identifier: clinicaltrials.gov. Identifier: NCT02905032.
Volume
11
Issue
2
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular
Subjects
Scopus EID
2-s2.0-85123285690
PubMed ID
Source
Journal of the American Heart Association
ISSN of the container
2047-9980
Sponsor(s)
The trial was funded by and conducted independently of the National Heart, Lung, and Blood Institute of the US National Institutes of Health (RO1 HL131535-01 and RO1 HL131535-03S1). The funding body had no influence on the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Sources of information:
Directorio de Producción CientÃfica
Scopus